Advances in hypertrophic cardiomyopathy: What the cardiologist needs to know

Area of Science:

• Cardiology
• Genetics
• Molecular Biology

Background:

• Hypertrophic cardiomyopathy (HCM) is the most prevalent genetic heart disease, defined by unexplained left ventricular hypertrophy.
• Despite advances in genetic sequencing, causative mutations remain unidentified in about 50% of HCM cases.
• Emerging research suggests distinct HCM subgroups, moving beyond the traditional sarcomere-centric view.

Purpose of the Study:

• To review recent advancements in understanding Hypertrophic Cardiomyopathy.
• To summarize new knowledge on diagnosis, sudden cardiac death risk, and therapeutic strategies.
• To highlight the significance of newly identified HCM subgroups.

Main Methods:

• Review of recent HCM registries and research findings.
• Analysis of clinical data differentiating HCM subgroups.
• Synthesis of current knowledge on diagnosis and management.

Main Results:

• Identification of two distinct HCM subgroups: sarcomere-positive and nonfamilial.
• Sarcomere-positive HCM patients often present younger, with more fibrosis and worse prognosis.
• Nonfamilial HCM patients exhibit different clinical and phenotypic characteristics.
• Advances in sudden cardiac death risk stratification and therapeutic approaches.

Conclusions:

• HCM is a complex, heterogeneous disease requiring tailored management strategies.
• Recognizing distinct HCM subgroups is crucial for personalized patient care.
• Ongoing research continues to refine our understanding and treatment of HCM.